<DOC>
	<DOC>NCT00964002</DOC>
	<brief_summary>RATIONALE: Efavirenz may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well efavirenz works in treating patients with metastatic prostate cancer.</brief_summary>
	<brief_title>Efavirenz in Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES: Primary - To assess the effect of efavirenz on the non-PSA progression rate at 3 months in patients with castration-refractory metastatic prostate cancer. Secondary - To assess the effect of efavirenz on the PSA response at 3 months. - To assess the effect of efavirenz on overall survival. - To assess the effect of efavirenz on PSA progression-free survival. - To assess the effect of efavirenz on symptomatic progression-free survival. - To assess the tolerability and safety profile of efavirenz. OUTLINE: This is a multicenter study. Patients receive oral efavirenz once daily in the absence of disease progression or unacceptable toxicity.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>DISEASE CHARACTERISTICS: Histologically confirmed prostate cancer Metastatic disease Castrationrefractory disease No clinical symptoms related to disease progression PATIENT CHARACTERISTICS: WHO performance status 02 PRIOR CONCURRENT THERAPY: Not specified</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>